Cargando…
Targeting epigenetic regulators to overcome drug resistance in cancers
Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic regulation is a heritable change in gene expressions independent of nucleotide sequence changes. As the common epigenetic regulation mechanisms, DNA methylation, histone modification, and non-coding RNA regula...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935618/ https://www.ncbi.nlm.nih.gov/pubmed/36797239 http://dx.doi.org/10.1038/s41392-023-01341-7 |
_version_ | 1784890055110688768 |
---|---|
author | Wang, Nan Ma, Ting Yu, Bin |
author_facet | Wang, Nan Ma, Ting Yu, Bin |
author_sort | Wang, Nan |
collection | PubMed |
description | Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic regulation is a heritable change in gene expressions independent of nucleotide sequence changes. As the common epigenetic regulation mechanisms, DNA methylation, histone modification, and non-coding RNA regulation have been well studied. Increasing evidence has shown that aberrant epigenetic regulations contribute to tumor resistance. Therefore, targeting epigenetic regulators represents an effective strategy to reverse drug resistance. In this review, we mainly summarize the roles of epigenetic regulation in tumor resistance. In addition, as the essential factors for epigenetic modifications, histone demethylases mediate the histone or genomic DNA modifications. Herein, we comprehensively describe the functions of the histone demethylase family including the lysine-specific demethylase family, the Jumonji C-domain-containing demethylase family, and the histone arginine demethylase family, and fully discuss their regulatory mechanisms related to cancer drug resistance. In addition, therapeutic strategies, including small-molecule inhibitors and small interfering RNA targeting histone demethylases to overcome drug resistance, are also described. |
format | Online Article Text |
id | pubmed-9935618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-99356182023-02-18 Targeting epigenetic regulators to overcome drug resistance in cancers Wang, Nan Ma, Ting Yu, Bin Signal Transduct Target Ther Review Article Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic regulation is a heritable change in gene expressions independent of nucleotide sequence changes. As the common epigenetic regulation mechanisms, DNA methylation, histone modification, and non-coding RNA regulation have been well studied. Increasing evidence has shown that aberrant epigenetic regulations contribute to tumor resistance. Therefore, targeting epigenetic regulators represents an effective strategy to reverse drug resistance. In this review, we mainly summarize the roles of epigenetic regulation in tumor resistance. In addition, as the essential factors for epigenetic modifications, histone demethylases mediate the histone or genomic DNA modifications. Herein, we comprehensively describe the functions of the histone demethylase family including the lysine-specific demethylase family, the Jumonji C-domain-containing demethylase family, and the histone arginine demethylase family, and fully discuss their regulatory mechanisms related to cancer drug resistance. In addition, therapeutic strategies, including small-molecule inhibitors and small interfering RNA targeting histone demethylases to overcome drug resistance, are also described. Nature Publishing Group UK 2023-02-17 /pmc/articles/PMC9935618/ /pubmed/36797239 http://dx.doi.org/10.1038/s41392-023-01341-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Wang, Nan Ma, Ting Yu, Bin Targeting epigenetic regulators to overcome drug resistance in cancers |
title | Targeting epigenetic regulators to overcome drug resistance in cancers |
title_full | Targeting epigenetic regulators to overcome drug resistance in cancers |
title_fullStr | Targeting epigenetic regulators to overcome drug resistance in cancers |
title_full_unstemmed | Targeting epigenetic regulators to overcome drug resistance in cancers |
title_short | Targeting epigenetic regulators to overcome drug resistance in cancers |
title_sort | targeting epigenetic regulators to overcome drug resistance in cancers |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935618/ https://www.ncbi.nlm.nih.gov/pubmed/36797239 http://dx.doi.org/10.1038/s41392-023-01341-7 |
work_keys_str_mv | AT wangnan targetingepigeneticregulatorstoovercomedrugresistanceincancers AT mating targetingepigeneticregulatorstoovercomedrugresistanceincancers AT yubin targetingepigeneticregulatorstoovercomedrugresistanceincancers |